Indication: Hodgkin Lymphoma

A Phase III, Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Sub-indication: Hodgkin Lymphoma

Study Type: Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Sponsor: COG

Search our entire site.